 |
| 권세창 차바이오그룹 R&D사업화 총괄 부회장. (사진제공=차바이오그룹) |
[Apha Biz=(Chicago) Reporter Paul Lee] Cha Byung-won and Cha Bio Group have appointed Kwon Se-chang (photo), former CEO of Hanmi Pharmaceutical, as vice chairmen of R&D commercialization. Kwon also serves as a professor of special training at Cha Medical University.
According to related industries on the 12th, Vice Chairman Kwon is regarded as a representative of Hanmi Pharmaceutical's transformation into a new drug development-oriented company. Sanofi, Janssen, Lily, and MSD (US Merck) played a pivotal role in global technology exports.
Kwon graduated from Yonsei University with a degree in biochemistry in 1986 and received a Ph.D. in animal resources science from Seoul National University. He joined Hanmi Pharmaceutical in 1996 and served as director of the research center and chief executive officer of R&D, leading the global new drug project of Hanmi Pharmaceutical.
It has applied for more than 1,000 patents, playing a key role in developing Hanmi Pharmaceutical's proprietary platform technology, "Labscovery." Recently, Lapscovery-based biopharmaceutical neutropenia anti-cancer drug was approved by the U.S. Food and Drug Administration (FDA) for the first time in Korea in 2022, establishing the foundation for the development of a new drug for Hanmi Pharmaceutical. He served as chairman of the R&D Policy Committee of the Korea Pharmaceutical Bio Association, chairman of the Pharmacist System Committee, and vice president of the Korea Applied Drug Association.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
